Omnicell (NASDAQ:OMCL) Upgraded by Wells Fargo & Company to Overweight Rating

Omnicell (NASDAQ:OMCL - Get Free Report) was upgraded by stock analysts at Wells Fargo & Company from an "equal weight" rating to an "overweight" rating in a research note issued to investors on Wednesday, Marketbeat.com reports. The brokerage currently has a $35.00 price target on the stock, up from their previous price target of $31.00. Wells Fargo & Company's price target points to a potential upside of 25.00% from the company's current price.

Several other brokerages have also weighed in on OMCL. StockNews.com lowered Omnicell from a "buy" rating to a "hold" rating in a research report on Saturday, May 3rd. Benchmark dropped their price target on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Omnicell from $44.00 to $36.00 and set a "neutral" rating on the stock in a research report on Thursday, March 20th. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $46.50.

Omnicell Price Performance

Shares of NASDAQ OMCL opened at $28.00 on Wednesday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37. The business has a 50-day simple moving average of $31.89 and a two-hundred day simple moving average of $39.80. The company has a market cap of $1.31 billion, a PE ratio of 103.71, a P/E/G ratio of 7.53 and a beta of 0.78. Omnicell has a fifty-two week low of $22.66 and a fifty-two week high of $55.75.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.16 by $0.10. Omnicell had a return on equity of 3.82% and a net margin of 1.13%. The firm had revenue of $269.67 million during the quarter, compared to analyst estimates of $260.18 million. During the same quarter in the previous year, the business earned $0.03 EPS. Omnicell's revenue for the quarter was up 9.5% compared to the same quarter last year. As a group, equities analysts expect that Omnicell will post 1.09 EPS for the current fiscal year.

Institutional Investors Weigh In On Omnicell

A number of institutional investors have recently modified their holdings of OMCL. Franklin Resources Inc. increased its position in shares of Omnicell by 49.9% during the 3rd quarter. Franklin Resources Inc. now owns 30,807 shares of the company's stock valued at $1,316,000 after purchasing an additional 10,260 shares during the period. Accurate Wealth Management LLC raised its position in Omnicell by 33.4% during the fourth quarter. Accurate Wealth Management LLC now owns 28,369 shares of the company's stock valued at $1,199,000 after acquiring an additional 7,109 shares in the last quarter. Arkadios Wealth Advisors increased its holdings in shares of Omnicell by 27.6% during the 4th quarter. Arkadios Wealth Advisors now owns 43,454 shares of the company's stock valued at $1,935,000 after acquiring an additional 9,404 shares during the last quarter. SG Americas Securities LLC lifted its stake in shares of Omnicell by 56.5% in the fourth quarter. SG Americas Securities LLC now owns 39,359 shares of the company's stock worth $1,752,000 after buying an additional 14,202 shares during the last quarter. Finally, Exchange Traded Concepts LLC increased its position in Omnicell by 6.7% during the fourth quarter. Exchange Traded Concepts LLC now owns 319,682 shares of the company's stock worth $14,232,000 after acquiring an additional 20,031 shares during the period. Institutional investors own 97.70% of the company's stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.